


Express Mail Label
No. EL937979316US

WSHU 2036.1
PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Douglas F. Covey

Serial No. 10/007,450

Filed November 5, 2001

Confirmation No. 3348

For MODIFIED, HYDROXY-SUBSTITUTED AROMATIC STRUCTURES
HAVING CYTOPROTECTIVE ACTIVITY

February 20, 2002

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS,
SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicant submits copies of references 1-25, 27-30, 32, 33, 35-38, 40-42 and 44-51 of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein. Copies of references 26, 31, 34, 39, 43, 52 and 53 have been ordered but have not yet been received. We will supplement this Information Disclosure Statement with copies of these references as soon as they have been received.


Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Derick E. Allen".

Derick E. Allen, Reg. No. 43,468
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

DEA/dep

GP/1614
RECEIVED
FEB 27 2002
TECH CENTER 1600/2900
MAR 3-23-02



RECEIVED

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/007,450
				Filing Date	November 5, 2000
				Confirmation Number	3348
				First Named Inventor	Douglas F. Covey
				Group Art Unit	1614
				Examiner Name	#4
Sheet	1	of	5	Attorney Docket No.	WSHU 2036.1

TECH CENTER 1600/2800
FEB 27 2002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	3,472,885		Bucourt et al.	10-14-1969
	2	4,330,540		Zeelen	05-18-1982
	3	4,617,298		Bodor et al.	10-14-1986
	4	4,786,647		Simpkins et al.	11-22-1988
	5	5,554,601		Simpkins et al.	09-10-1996
	6	5,554,604		Bonfils et al.	10-10-1996
	7	5,679,668		Bonfils et al.	10-21-1997
	8	5,824,672		Simpkins et al.	10-20-1998
	9	5,843,934		Simpkins	12-01-1998
	10	5,859,001		Simpkins et al.	01-12-1999
	11	5,877,169		Simpkins	03-02-1999
	12	5,914,325		Droescher et al.	06-22-1999
	13	5,939,407		Landfield	08-17-1999
	14	5,972,923		Simpkins et al.	10-26-1999

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known		FEB 27 2002 TECH CENTER 1600/2900	
				Application Number			10/007,450
				Filing Date			November 5, 2000
				Confirmation Number			3348
				First Named Inventor			Douglas F. Covey
				Group Art Unit			1614
				Examiner Name			
Sheet	2	of	5	Attorney Docket No.		WSHU 2036.1	

	15	6,197,833	B1	Simpkins et al.	03-06-2001
	16	6,207,658	B1	Simpkins et al.	03-27-2001
	17	6,265,147	B1	Mobley et al.	07-24-2001

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	18	CA	1 167 837		Akzo N.V.	05-22-1984	
	19	EP	0 069 424	B1	Akzo N.V.	01-12-1983	
	20	GB	1 298 587		American Home Products Corporation	12-06-1972	
	21	WO	95/13076	A1	JENAPHARM GMBH	05-18-1995	
	22	WO	97/03661	A1	University of Florida Research Foundation, Incorporated	02-06-1997	
	23	WO	99/26630	A1	University of Florida Research Foundation, Incorporated	06-03-1999	
	24	WO	00/63228	A1	Schering Aktiengesellschaft	10-26-2000	
	25	WO	01/10430	A2	University of Florida Research Foundation, Inc.	02-15-2001	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/007,450
				Filing Date	November 5, 2001
				Confirmation Number	3348
				First Named Inventor	Douglas F. Covey
				Group Art Unit	1614
				Examiner Name	
Sheet	3	of	5	Attorney Docket No.	WSHU 2036.1

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	26	Akhter et al., Stroke, Vol. 25 (1994) p. 418.	
	27	A. ALLAIS et al. "3-(β-Dialkylaminoethoxy)estra-1,3,5(10)-trienes" Chemical Abstracts, Vol. 70, No. 25; Abstract No. 115418e (1969) p. 381.	
	28	K. BARNIKOL-OETTLER et al. "Preparation of Estradiol 3-methyl Ether" Chemical Abstracts, Vol. 160, No. 25, Abstract No. 106:214199c (1987).	
	29	C. BEHL et al. "17-βEstradiol Protects Neurons from Oxidative Stress-Induced Cell Death in vitro" Biochemical and Biophysical Research Communications, Vol. 216, No. 2 (1995) pp. 473-482.	
	30	G.C. BUZBY et al. "Totally Synthetic Steroid Hormones. XIII. The Chemical Resolution of Some Racemic Estrane, 13β-Ethylgonane, and 13β-n-Propylgonane Derivatives and the Preparation of Some Estrane and 13β-Ethylgonane Derivatives of Unnatural Configuration" Journal of Medicinal Chemistry, Vol. 10 (1967) pp. 199-204.	
	31	T. FAN et al. "ZYC-13, the enantiomer of 1,3,5(10)-estratriene 3-OL, exerts neuroprotective effects in vitro and in vivo" Presented at the 26th Soc. for Neuroscience Meeting, 11/4/00 to 11/9/00.	
	32	Y. GOODMAN et al. "Estrogens Attenuate and Corticosterone Exacerbates Excitotoxicity, Oxidative Injury, and Amyloid β-Peptide Toxicity in Hippocampal Neurons" Journal of Neurochemistry, Vol. 66, No. 5 (1996) pp. 1836-1844.	
	33	P. GREEN et al. "The Nonfeminizing Enantiomer of 17β-Estradiol Exerts Protective Effects in Neuronal Cultures and a Rat Model of Cerebral Ischemia" Endocrinology, Vol. 142, No. 1 (2001) pp. 400-406.	
	34	HALL et al., J. Cer. Blood Flow Metab., Vol. 11 (1991) p. 292.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/007,450
				Filing Date	November 5, 2001
				Confirmation Number	3348
				First Named Inventor	Douglas F. Covey
				Group Art Unit	1614
				Examiner Name	
Sheet	4	of	5	Attorney Docket No.	WSHU 2036.1

	35	H. KANEKO et al. "The Synthesis of 2- and 4-Alkoxyethylestrogens" Chem. Pharm. Bull., Vol. 12, No. 2 (1964) pp. 196-203.	
	36	M. A. LEVITT et al. "Reduction of Infarct Size During Myocardial Ischemia and Reperfusion by Lazaroid U-74500A, a Nonglucocorticoid 21-Aminosteroid" J. of Cardiovascular Pharmacology, Vol. 23, No. 1 (1994) pp. 136-140.	
	37	W. LUNN et al. "The Adamantyl Carbonium Ion as a Dehydrogenating Agent, its Reactions with Estrone" Tetrahedron Letters, Vol. 24, No. 23 (1968) pp. 6773-6776.	
	38	C. MILLER et al. "In vitro antioxidant effects of estrogens with a hindered 3-OH function on the copper-induced oxidation of low density lipoprotein" Steroids, Vol. 61 (1996) pp. 305-308.	
	39	MOORADIAN, J. Steroid Biochem. Molec. Biol., Vol. 45 (1993) pp. 509-511.	
	40	M. NAKANO et al. "Novel and Potent Biological Antioxidants on Membrane Phospholipid Peroxidation: 2-Hydroxy Estrone and 2-Hydroxy Estradiol" Biochemical and Biophysical Research Communications, Vol. 142, No. 3 (1987) pp. 919-924.	
	41	E. NIKI et al. "Antioxidants in Relation to Lipid Peroxidation" Chemistry and Physics of Lipids, Vol. 44, Nos. 2-4 (1987) pp. 227-253.	
	42	T. PATTON et al. "Estrogens. IV. The Synthesis of 2- and 4-Alkylestrones" Journal of Organic Chemistry, Vol. 27, No. 3 (1962) pp. 910-914.	
	43	E. J. PERES et al. "762.7 - Structure-Activity Relationship of Estratrienes Against Glutamate Toxicity in a Mouse Hippocampal Cell Line" Presented at the 26th Soc. for Neuroscience Meeting, 11/4/00 to 11/9/00.	
	44	L. PROKAI et al. "Synthesis and Biological Evaluation of 17 β -Alkoxyestra-1,3,5(10)-trienes as Potential Neuroprotectants Against Oxidative Stress" J. Med. Chem., Vol. 44, No. 1 (2001) pp. 110-114.	
	45	W. ROMER et al. "Novel estrogens and their radical scavenging effects, iron-chelating, and total antioxidative actives: 17 α -substituted analogs of $\Delta^{9(11)}$ -dehydro-17 β -estradiol" Steroids, Vol. 62 (1997) pp. 688-694.	


Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/007,450
				Filing Date	November 5, 2001
				Confirmation Number	3348
				First Named Inventor	Douglas F. Covey
				Group Art Unit	1614
				Examiner Name	
Sheet	5	of	5	Attorney Docket No.	WSHU 2036.1



RECEIVED
 FEB 27 2002
 TECH CENTER 1600/2900

	46	W. ROMER et al. "Novel "scavestrogens" and their radical scavenging effects, iron-chelating, and total antioxidative actives: $\Delta^{8,9}$ -dehydro derivatives of 17- α -estradiol and 17 β -estradiol" Steroids, Vol. 62 (1997) pp. 304-310.	
	47	A.G. SCHERING, "Preparation of ent-steroids as Selectively Effective Estrogens" Chemical Abstracts, Vol. 133, No. 21, Abstract No. 133:296594x (2000) p. 766-767.	
	48	A. SEELIG et al. "A method to determine the ability of drugs to diffuse through the blood-brain barrier" Proc. Natl. Acad. Sci. USA, Vol. 91 (1994) pp. 68-72.	
	49	L. TIETZE et al. "Synthesis of new 16-spirosteroids" Steroids, Vol. 59 (1994) pp. 305-309.	
	50	J. WILSON et al. "U83836E Reduces Secondary Brain Injury in a Rabbit Model of Cryogenic Trauma" Journal of Trauma, Vol. 39, No. 3 (1995) pp. 473-479.	
	51	A. WUNDERLI et al. "Geometry of the Activated Complex of the Thermal and Charge-Induced Aromatic Para to Ortho Claisen Rearrangement" Helvetica Chimica Acta, Vol. 56 (1973) pp. 989-1011.	
	52	S. XIA et al. "A Novel Estrogen Analog, Inactive at the Estrogen Receptor, is Neuroprotective" Presented at the 26th Soc. for Neuroscience Meeting, 11/4/00 to 11/9/00.	
	53	S-H. YANG et al. "Neuroprotective Effects of a Novel Non-Recptor Binding Estrogen Analogue During Stroke" Presented at the 26th Soc. for Neuroscience Meeting, 11/4/00 to 11/9/00.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.